Alliances to Strengthen Los Angeles County’s Life Sciences Community
California Life Sciences Association (CLSA), the nation’s largest statewide public policy and business leadership organization representing California’s leading life sciences innovators, today announced new strategic partnerships with LA BioMed and Lab Launch, and the unveiling of its Los Angeles satellite office, to regularly engage and bolster Los Angeles County’s life sciences community.
Dr. Joaquín Madrenas Brings Decades of Research Experience to the Institute
Further strengthening its research enterprise, LA BioMed announced today the addition of a new chief scientific officer to its leadership team, Joaquín (Quim) Madrenas, MD, PhD. Dr. Madrenas brings decades of experience as a researcher, physician, educator and administrator to one of the nation’s leading nonprofit independent research institutes.
New Study of Four Common Conditions Finds ICU Use Didn’t Improve Mortality Rates
LOS ANGELES – With the use of intensive care units (ICUs) on the rise in many hospitals, researchers at LA BioMed and UCLA examined ICU usage and found patients who were admitted to these units underwent more costly and invasive procedures but didn’t have better mortality rates than hospitalized patients with the same medical conditions who weren’t admitted to the ICU.
New Study Finds ARB and ACEI Linked to Similar Results
LOS ANGELES – With cardiovascular disease being the No. 1 cause of death in end-stage kidney disease patients on peritoneal dialysis, a new study examined two classes of medications commonly prescribed to prevent cardiovascular events in these patients and found no significant difference in outcomes.
Clinical Stage Adult Stem Cell Company Expands Portfolio of Clinical Indications
Creative Medical Technologies, Inc. (CMT) announced today the signing of a license agreement with LA BioMed granting exclusive rights for United States patent application # 14/508763, covering the use of stem cells for treatment of male infertility. In the patent application and a subsequent publication, Ronald S.
New Study Finds a 16% Reduction in Cardiovascular Events with the Use of ACEIs and ARBs
Two classes of blood pressure medications, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are associated with a 16% lower risk of strokes, heart attacks and death in patients with end-stage renal disease who are undergoing peritoneal dialysis, a new study in the journal, Nephrology Dialysis Transplantation, reports.
They Find Study “Reassuring” and Say it Has Lessons for Cardiologists and Oncologists
In an editorial in the New England Journal of Medicine, LA BioMed Researchers Rowan T. Chlebowski, MD, PhD, and Matthew J. Budoff, MD, said a new study of the long-term use of aromatase inhibitors to prevent the recurrence of certain types of breast cancer is “reassuring,” and they urged oncologists and cardiologists to combine prevention and early detection to prevent disease.
The National Institute of Neurological Disorders and Stroke recently awarded over $1.7 million in grant funding to Phoenix Nest, Inc. to continue its partnership with the Los Angeles Biomedical Institute (LA BioMed) to research the development of therapies for treating different forms of a devastating inherited genetic disorder, Sanfilippo disease, also known as MPS III.
Patients with diabetic ketoacidosis (DKA) face a much higher risk of succumbing to a deadly fungal infection, known as mucormycosis, than healthy patients. A new study suggests a simple treatment of sodium bicarbonate, or baking soda, could prevent the spread of mucormycosis in patients with DKA.
New Data from Women’s Health Initiative Dietary Modification Trial Finds Long-term Dietary Changes Improves Breast Cancer Survival Rates
Women who stayed on a low fat diet for approximately eight years reduced their risk of death from invasive breast cancers and improved their survival rates when compared with women who had not followed the dietary regimen, according to a study presented at a clinical trial plenary session, entitled "Transformative Clinical Trials in Breast Cancer," at the American Association for Cancer Research (AACR) annual meeting.